Horizon scanning: Updated survival data for phase II trial of bavituximab for second-line treatment of non-small cell lung cancer

Source: BioSpace Area: News Peregrine Pharmaceuticals, Inc. has reported updated survival data from its randomised, double-blind, placebo-controlled phase IIb trial evaluating bavituximab plus docetaxel versus docetaxel plus placebo in 121 patients with second-line stage IIIb or IV non-squamous, non-small cell lung cancer (NSCLC). See previous NELM report for study details.   The data indicate a median overall survival of 11.7 months in the bavituximab arm compared to 7.3 months in the control arm (hazard ratio=0.73; p value=0.217).  The results also demonstrated that bavituximab was well-tolerated with no significant differences in adverse events between the trial arms.   Additional data from the trial, including updated subgroup analysis and safety data will be reported at an upcoming scientific meeting.
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news